ABRAXANE In Combination With Gemcitabine And Epirubicin Evaluated As Neoadjuvant Trea
 

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced the presentation of preliminary results from a single-arm, open-label, Phase II clinical trial evaluating ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin- bound) in combination with gemcitabine and epirubicin for the treatment of patients with locally advanced breast cancer (neoadjuvant treatment).

More...